AKT1 and thyroid gland carcinoma: Previous studies have shown that resistance to BRAF kinase inhibitors in BRAF-mutant thyroid cancer is due to the reactivation of the MAPK/ERK and PI3K/AKT pathwa (Montero et al. 2013).